Clear Cell Renal Cell Carcinoma Clinical Trials in New Haven, Connecticut

4 studies are recruiting for clear cell renal cell carcinoma in New Haven, Connecticut right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

    This phase II trial tests the effect of botensilimab and balstilimab before surgery (neoadjuvant) in treating patients with high-risk clear cell renal cell cancer that has not spread from where it first started to other areas of the body (non-metastatic). The current standard treatment for patients…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Yale University Cancer Center LAO, New Haven, Connecticut
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT07516366 on ClinicalTrials.gov

  2. Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

    This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attac…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Yale University, New Haven, Connecticut
    Locations
    425 in total
    Run by
    Alliance for Clinical Trials in Oncology

    See if you can join NCT06661720 on ClinicalTrials.gov

  3. Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

    The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Xencor Investigative Site, New Haven, Connecticut
    Locations
    26 in total
    Run by
    Xencor, Inc.

    See if you can join NCT05433142 on ClinicalTrials.gov

  4. Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

    The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monother…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    NEO-811 Connecticut Site, New Haven, Connecticut
    Locations
    12 in total
    Run by
    Neomorph, Inc

    See if you can join NCT07300241 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.